Yabing Guo

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

Masatoshi Kudo, Zhenggang Ren, Yabing Guo et al. · The Lancet · 2025 · 251 citations

Medicine, Oncology, Pharmacotherapy +16

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Shukui Qin, Masatoshi Kudo, Tim Meyer et al. · JAMA Oncology · 2023 · 249 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis

Haiyu Wang, Biao Wen, Xianyi Chang et al. · Journal of Hepatology · 2020 · 85 citations

Medicine, Pathology, Radiology +13